ISPOR Fast Facts: The Global Pricing Pendulum: Value Assessment, and the Future of Pharmaceutical Innovation in A World Driven by Trade Incentives

Neal Masia, PhD, Co-Founder and CEO of EntityRisk, will speak at this ISPOR Fast Facts Session. This session will examine how shifting global health policies and fragmented regulatory environments are reshaping pharmaceutical R&D, market prioritization, and the consequential effects.

Upcoming: Let's meet in Philadelphia!

Join EntityRisk and industry leaders for a discussion on how HEOR and Market Access professionals are navigating the evolving policy, access, and value landscapes.

Come visit us at Booth #805.

About EntityRisk

EntityRisk integrates globally renowned health economics and policy expertise with PROVEN™, our advanced modelling software, to predict health outcomes, identify maximum value-based pricing, and substantiate evidence-generation investments.

10 of the Top 20 Biopharma Companies work with EntityRisk to navigate the shifting policy landscape and confidently choose and defend justifiable prices, inform evidence investments, and communicate and win on value.

10 / 20

Top Biopharma Companies

1,300+

Quality Checks

5

ML Modules

Leverage software built by a team with world- class scientific, engineering and industry credentials.